Alaethes Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Alaethes Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$653K	Hold	5,110	–	–	0.19%	84
2025 Q4	$623K	Hold	5,110	–	–	0.18%	85
2025 Q3	$512K	Hold	5,110	–	–	0.15%	89
2025 Q2	$424K	Hold	5,110	–	–	0.13%	90
2025 Q1	$414K	Hold	5,110	–	–	0.15%	92
2024 Q4	$460K	Sell	5,110 -20	-0.4%	-$1.94K	0.16%	91
2024 Q3	$507K	Sell	5,130 -460	-8%	-$45.2K	0.19%	91
2024 Q2	$518K	Sell	5,590 -290	-5%	-$26K	0.21%	88
2024 Q1	$558K	Sell	5,880 -20	-0.3%	-$1.86K	0.24%	91
2023 Q4	$527K	Sell	5,900 -885	-13%	-$65.7K	0.25%	93
2023 Q3	$495K	Hold	6,785	–	–	0.27%	91
2023 Q2	$565K	Hold	6,785	–	–	0.31%	89
2023 Q1	$517K	Hold	6,785	–	–	0.3%	90
2022 Q4	$563K	Buy	6,785 +375	+6%	+$30.4K	0.39%	81
2022 Q3	$508K	Sell	6,410 -10	-0.2%	-$843	0.37%	84
2022 Q2	$477K	Sell	6,420 -525	-8%	-$39.4K	0.35%	84
2022 Q1	$624K	Sell	6,945 -125	-2%	-$11.5K	0.4%	81
2021 Q4	$792K	Hold	7,070	–	–	0.5%	77
2021 Q3	$889K	Hold	7,070	–	–	0.65%	64
2021 Q2	$957K	Sell	7,070 -10	-0.1%	-$1.31K	0.74%	52
2021 Q1	$960K	Buy	+7,080	New	+$1.06M	0.89%	40

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Alaethes Wealth's XBI Position: Q1 2026 in Review

Alaethes Wealth held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 5,110 shares worth $653K. The position accounts for 0.19% of the portfolio, ranked #84.

Alaethes Wealth first reported a position in XBI in Q1 2021 and has held it in 21 quarters since. The position peaked at $960K in Q1 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Alaethes Wealth held 5,110 shares of State Street SPDR S&P Biotech ETF worth $653K as of Q1 2026.
Alaethes Wealth left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.19% of Alaethes Wealth's portfolio in Q1 2026, its #84 holding.
Alaethes Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 21 quarters since.
Alaethes Wealth's State Street SPDR S&P Biotech ETF position peaked at $960K in Q1 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Alaethes Wealth's 13F filing for Q1 2026, filed 12 May 2026.